Bristol-Myers Squibb Company (ETR:BRM)
52.88
-0.16 (-0.30%)
Feb 21, 2025, 5:35 PM CET
Bristol-Myers Squibb Company Employees
Bristol-Myers Squibb Company had 34,100 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
34,100
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
€1,368,122
Profits / Employee
€253,457
Market Cap
108.40B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
Siemens Healthineers AG | 72,000 |
Merck KGaA | 62,908 |
Bayer Aktiengesellschaft | 96,931 |
Fresenius SE & Co. KGaA | 193,865 |
Sartorius Aktiengesellschaft | 13,528 |
Fresenius Medical Care AG | 119,845 |
Carl Zeiss Meditec AG | 5,730 |
SCHOTT Pharma AG & Co. KGaA | 4,690 |
Bristol-Myers Squibb Company News
- 21 hours ago - Insider trades: JPMorgan, Bristol-Myers Squibb among notable names this week - Seeking Alpha
- 1 day ago - Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success - Seeking Alpha
- 2 days ago - Bristol-Myers Squibb (BMY) Announces Executive Vice President's Retirement - GuruFocus
- 3 days ago - Lightning Round: Own Arm Holdings for the long-term, says Jim Cramer - CNBC
- 3 days ago - Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer - Wallstreet:Online
- 5 days ago - Bristol-Myers Squibb Co (BMY) Announces Positive Five-Year Results for Sotyktu in Psoriasis ... - GuruFocus
- 6 days ago - New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis - Benzinga
- 9 days ago - Bristol-Myers Squibb Co (BMY) Announces Phase 3 Trial Results for Opdualag⢠- GuruFocus